04Nov 2023
Iptacopan as an alternative complement pathway inhibitor for IgA nephropathy- Study Results

Iptacopan as an alternative complement pathway inhibitor for IgA nephropathy- Study Results

In this Phase 2 study, iptacopan, an oral alternative complement inhibitor targeting Factor B, showed a significant dose-response effect in patients with immunoglobulin A nephropathy (IgAN). Iptacopan achieved a 23% reduction in 24-hour urine protein-to-creatinine ratio at three months, with sustained benefits at six months. The treatment demonstrated safety, complement pathway inhibition, and persistent proteinuria reduction, supporting its advancement to Phase 3 trials.

  • #nephrology

Like

Save

Share